Supplementary Table Author Year Age Sex Stage Histologic HL

supplementary table author year age sex stage, histologic hl type viruses bilirubin on admission (direct) (mg/d) tr

Supplementary Table
Author
Year
Age
Sex
Stage, Histologic HL Type
Viruses
Bilirubin on admission (Direct) (mg/d)
Treatment
Outcome/ Cause of death
1
Our patient
2020
31
F
N.S. IIA
EBV, CMV
21.5 (13.7)
UDCA, Dexamethasone, ABVD (6 cycles)
Remission
2
Anugwom C. et al [7]
2020
27
F
6 (5.4)
1) Radiotherapy, Dexamethazone, Rituximab, Gemcitabine and Cisplatin
2) ABVD
Remission
3
Raquel D.Greca et al [10]
2019
25
F
N.S.
19.6 (14)
Prednisone, UDCA , AB (1 cycle), ABVD (5 cycles)
Slight clinical improvement
4
Fong Min et al [21]
2019
39
F
III
9.88 (8.07)
UDCA, Prednisone (cycles 1-7) CP (almost full dose, cycles 1-6)
Procarbazine ( cycles 3-6) Brentuximab (cycles 4-6)
Remission
5
Das Aniban et al [22]
2018
7
M
IVB
CMV
6 (3.4)
Prednisolone Bleomycin Darcarbazine (2 weeks), DHAP ( 3 cycles)
Death/Hepatic failure
6
Bakhit Mena et al [11,23]
2016
25
M
IIB
6.2 (3.9)
Nitrogen Mustard , Corticosteroids , Radiotherapy Ultimately
Gemcitabine/Oxaliplatin
Remission
7
Bakhit Mena et al [23]
2016
41
F
N.S. IIA
Increased
UDCA, Rifampin, DHAP (50% reduced cytarabine), Radiotherapy
Death/ Unknown causes
8
Sathyanarayanan V. et al [18]
2016
39
M
N.S. IIIB
10
Mechlorethamine ( 2 doses), AVD (Cycle 1A 50% dose reduction, Cycle 1B
25% dose reduction, 5 Cycles full)
Remission
9
Yeh P. et al [24]
2014
75
M
M.C.
HAV, HBV, CMV, EBV
17.36
UDCA, ABVD
Death/Sepsis
10
Rota Scalabrini et al [1]
2014
42
F
N.S. IIB
18.3 (15.3)
UDCA, Prednisone, ABVD (6 cycles)
Remission
11
Hallen Karin et al [20]
2014
N.M.
M
N.S. IIB
HBV,CMV
6
Rituximab (weekly x 4), BEACOPP -Etoposide: 50% dose (5 cycles),
Doxorubicine: 60% dose for cycle 1 and 70% until the end, CP: 50% dose
for cycle 1 and 70% until the end
Remission
12
Nader K. et al [25]
2013
64
F
N.S
45
Gemcitabine, Dexamethasone, Cisplatin
Death/Hepatic failure, sepsis
13
Aleem A. et al [26]
2013
33
M
N.S. IIIB
5.14(4.32)
ABVD (1 cycle, 30% reduced dose), ESHAP (2 cycles, 50% increase in
methylprednisolone in the latter)
Death/Hepatic failure
14
Amer S. et al [8]
2013
40
M
III
4.2 (2.5)
ABVD
Remission
15
Wong Km. et al [13]
2013
38
M
M.C. IIA
14.8 (9.39)
1) ABVD (4 cycles) 2) Autologous
hematopoietic cell transplantation with BEAM
Remission
16
Umit H. [27]
2009
45
M
N.S.
HBV
20.3 (20)
ABVD (8 cycles) + 24 sessions of radiotherapy when HL presented 6
months prior Prednisolone after the diagnosis of VBDS
Remission
17
Pass AK. et al [9]
2008
10
M
M.C. IIIB
EBV
3.8
1) Nitrogen mustard, Prednisone, 2) Stanford V (initially
with 50% dose reduction of Adriamycin and vinblastine, 25%
dose reduction of vincristine, and full doses of bleomycin and VP-16)
3) rituximab (total of 4 doses), 4) IFRT
Death/ Aspiration
18
Pass AK. Et al [9]
2008
12
M
M.C. , N.S. IIIB
EBV
10.8 (6)
1) MOPP-ABV [nitrogen mustard, procarbazine (for 7 days),
prednisone (for 14 days), 50% dose adriamycin
and 50% dose vinblastine
and bleomycin, 2) 75% dose adriamycin and 75% dose vinblastine (cycle
4) and 100% (cycles 5 and 6), 3) IFRT
Intensifying VBDS/awaiting transplantation
19
Leeuwenburgh et al [28]
2008
17
M
N.S. IIIB
EBV
27.65
1) MOPP (2 courses), 2)50% reduced dose P(V)AG, 3) full dose PVAG (6
courses)
Remission
20
DeBenedet AT. et al [5]
2008
39
M
N.S. IIIA
29.5 (14.4)
Intravenous nitrogen mustard and dexamethasone the first and eighth
days of each month and oral dexamethasone daily (for 5 months)
Death/ Unknown causes
21
Ballonoff A. et al [4]
2008
22
M
N.S. IIA
26 (16)
1) Cyclophosphamide, dexamethasone, oral
prednisone, radiation, 2) Radiation alone, 3) Azathioprine, prednisone
Remission
22
Schmitt A. et al [29]
2006
46
M
IIIA
12.7 (7.7)
Empirical use of corticosteroids
Death/Sepsis
23
Han WS. et al [30]
2005
45
M
ΙΙΑ
Radiotherapy
Recurrent HL
24
Córdoba Iturriagagaitia A. et al [31]
2005
17
M
N.S. II
20
Bleomycin, cyclophosphamide, dacarbazine, methylprednisolone (8
cycles)
Remission
25
Guliter S. et al [32]
2004
46
N.M.
ΙΙΙΒ
15.55
Chemotherapy
Death/Sepsis
26
Kömürcü S. et al [33]
2002
23
M
M.C. IIIB
10.1 (4.8)
1) ABVD (6 cycles), 2) ABVD-MOPP (8 cycles), 3) DHAP (2 cycles), 3)
Cyclophosphamide, melphalan, cytosine arabinoside, and etoposide with
autologous PBSCT
Death/Hepatic failure
27
Ripoll C. et al [34]
2002
28
F
N.S. IIA
HAV
32.8
1) C-MOPP [(cyclophosphamide, vincristine, procarbazine and
prednisone) (2 cycles)], 2) Radiotherapy
Death/Hepatic failure
28
Ripoll C. et al [34]
2002
23
M
N.S. IIA
26.9
1) C-MOPP [(cyclophosphamide, vincristine, procarbazine and
prednisone) (1 cycle)], 2) ABVD (1 cycle), 3) Radiotherapy, 4) UDCA
and cholestyramine, 5) ABVD
Remission
29
Ozkan A. et al [35]
2001
3.5
M
N.S. IIIB
6.14
ABVD (1 cycle), Prednisolone, IV Immunoglobulin, UDCA
Death/Hepatic failure
30
Allory Y. [36]
2000
54
M
IIIB
2.98
Chemotherapy
Remission
31
Rossini MS. et al [12]
2000
38
M
M.C.
33.5 (22.7)
MOPP-ABV (four cycles), high dose Cyclophosphamide, Etoposide
Death/Hepatic failure
32
Yusuf MA. [37]
2000
5
M
IB
Corticosteroids and Chemotherapy
Death/ Hepatic failure
33
De Medeiros BC. et al [38]
1998
27
F
M.C.
23.4 (18.5)
MOPP
Death/Hepatic failure
34
De Medeiros BC. et al [38]
1998
50
F
N.S.
21.7 (16.3)
MOPP/ABV
Remission
35
Crosbie OM. et al [39]
1997
21
F
IIIB
14.3
UDCA, mustine Oncovin Procarbazine Prednisolone Monthly transfusions
Remission
36
Gottrand F. et al [19]
1997
3.5
M
M.C. II
HAV
50
VEBP(3 cycles), ABVP(2 cycles), Radiotherapy
Death/Hepatic failure
37
Hubscher SG. et al [3]
1993
26
M
N.S.
11.7
LOPP/EVA(1 cycle) EVAP (1 cycle) LOPP (1 cycle) miniBEAM (1 cycle)
Death/Pneumonia
38
Hubscher SG. et al [3]
1993
44
M
I
17.5
LOPP (1 cycle)
Death/Sepsis
39
Hubscher SG. et al [3]
1993
37
F
N.S.
LOPP/EVA(1 cycle) Ketoconazole
Death/ Kidney and respiratory failure
NOT CONFIRMED CASES
Author
Year
HL Treatment
Liver Biopsy
1
Barta SK. [40]
2006
YES
IC
2
Liangpunsakul S. [41]
2002
YES
Cholestatic hepatitis
3
Dourakis SP. [42]
1999
YES
Hepatocellural necrosis
4
Yalçin S. [43]
1999
NO
IC
5
Yalçin S. [43]
1999
YES
IC
6
Warner AS. [44]
1994
YES
IC
7
Jansen PLM. [45]
1994
YES
IC
8
Birrer MJ. [46]
1986
YES
IC
9
Lieberman DA. [47]
1986
NO
IC
10
Trewby PN. [48]
1979
YES
IC
11
Trewby PN. [48]
1979
NO
Mild portal hepatitis
12
Trewby PN. [48]
1979
YES
Lymphoma infiltration
13
Trewby PN. [48]
1979
NO
Lymphoma infiltration
14
Trewby PN. [48]
1979
YES
Mixed inflammatory and atypical histiocytes
15
Trewby PN. [48]
1979
YES
IC
16
Piken EP. [49]
1979
YES
IC
17
Perera DR. [50]
1974
YES
IC
18
Perera DR. [50]
1974
YES
IC
19
Perera DR. [50]
1974
YES
IC
20
Groth C. [51]
1972
YES
IC
21
Juniper K. [52]
1963
YES
IC
22
Bouroncle B. [2]
1962
YES
IC
23
Bouroncle B. [2]
1962
YES
IC
Abbreviations
AB: Adriamycin Bleomycin; ABVD: Adriamycin Bleomycin Vinblastine
Dacarbazine; AVD: Adriamycin Vinblastine Dacarbazine; BEACOPP:
Bleomycin, Etoposide Adriamycin Cyclophosphamide Oncovin Procarbazine
Prednisolone; BEAM: Carmustine (BCNU) Etoposide Cytarabine (Ara-C)
Melphalan; C-MOPP: Cyclophosphamide Vincristine (oncovin) Procarbazine
Prednisolone; CP: Chlorambucil Hydrochloride Prednisone; DHAP:
Dexamethasone High Dose Cytarabine (Ara-C) Platinol; ESHAP: Etoposide
Solu-Medrol High Dose Cytarabine (Ara-C) Platinol; EVA: Etoposide
Vinblastine Adriamycin
HL: Hodgkin’s Lymphoma; IC: Idiopathic Cholestasis; IFRT:
Involved-Field Radiation Therapy; LOPP: Chlorambucil Vincristine
Procarbazine Prednisone; MC: Mixed Cellularity; MOPP: Mustargen
Oncovin Procarbazine Prednisone; NS: Nodular Sclerosis; PBSCT:
Peripheral Blood Stem Cell Transplantation; PVAG: Prednisone
Vinblastine Adriamycin Gemcitabine; UDCA: Ursodeoxycholic Acid; VBDS:
Vanishing Bile Duct Syndrome; VEBP: Vincristine Etoposide Bleomycin
Prednisone; VP-16: Vepesid (etoposide);